As the year 2021 comes to a close, CancerNetwork sat down with Yael Cohen, MD, to discuss practice-changing clinical research in multiple myeloma that read out in 2021 and potential FDA updates that may take place in 2022.
As the year 2021 comes to a close, CancerNetwork sat down with Yael Cohen, MD, to discuss practice-changing clinical research in multiple myeloma that read out in 2021 and potential FDA updates that may take place in 2022.
DUARTE, Calif.--(BUSINESS WIRE)--City of Hope doctors presented data on an investigational bispecific antibody for multiple myeloma and the CMVPepVax, a City of Hope-developed vaccine against the cytomegalovirus, at this years ASH Annual Meeting. City of Hope continues to be a leader in innovative research on investigational immunotherapies for blood cancers and improving stem cell transplants, said Eileen Smith, M.D., City of Hopes Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma; IND submission on track for mid-2022 - - Data presented at ASH Annual Meeting support potential for CAR-iT cells to deliver allogeneic T cell therapies without risk for GVHD; cells chosen as initial focus of iT cell development program - - Company to host virtual research & development update today at 8:00 AM ET - PHILADELPHIA, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced updated preclinical data from the Companys CNTY-101 program and CAR-iT platform.
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today provided an update from the ongoing Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical hematopoietic stem cell transplant (HSCT)
DUBLIN--(BUSINESS WIRE)--The "Cell Isolation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global cell isolation market exhibited strong growth during 2015-2020
WASHINGTON, Dec. 14, 2021 /PRNewswire/ -- In a phase III trial presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) was not found to improve event-free survival over what was seen with standard of care as a second-line treatment for patients with aggressive non-Hodgkin lymphoma. The results, which come as a surprise after previous CAR-T trials have shown improved clinical outcomes, may reflect variability in the patient population, timing and administration of tisa-cel and stem cell transplants, and use of chemotherapy in real-world settings, according to researchers
Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma. In adults with relapsed/refractory diffuse large b-cell lymphoma (DLBCL), YTB323, an investigational, autologous CD19-directed CAR-T cell therapy, showed a favorable safety profile and efficacy across multiple dose levels, according to findings from a phase 1 trial (NCT03960840) presented at the 2021 ASH Annual Meeting and Exposition
DUBLIN--(BUSINESS WIRE)--The "CRISPR Technology Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global CRISPR technology market is expected to grow from $0.8 billion in 2020 to $0.95 billion in 2021 at a compound annual growth rate (CAGR) of 18.8%
By James Pethokoukis The United States has about 4 percent of the global population and accounts for nearly a quarter of global GDP.
For Dr.
Recent Comments